EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients (Record no. 78447)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 01963ngm a2200361 a 4500 |
001 - CONTROL NUMBER | |
control field | HST2056_1_2 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | UkLoHST |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
fixed length control field | m c |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr|cna|||a|||| |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | vz|czazum |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 080121s2009 enk|||||||||||s|||v|eng d |
028 50 - PUBLISHER NUMBER | |
Publisher number | 2056 |
Source | Henry Stewart Talks |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (UkLoHST)1123 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (UkLU-K)000947301 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | UkLU-K |
Language of cataloging | eng |
Transcribing agency | UkLU-K |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Hirsch, Fred R. |
Relator code | spk |
245 10 - TITLE STATEMENT | |
Title | EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients |
Medium | [electronic resource] / |
Statement of responsibility, etc. | Fred R. Hirsch. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Place of publication, distribution, etc. | London : |
Name of publisher, distributor, etc. | Henry Stewart Talks, |
Date of publication, distribution, etc. | 2009. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 1 online resource (1 streaming video file (36 min.) : |
Other physical details | color, sound). |
490 1# - SERIES STATEMENT | |
Series statement | Cancer therapy : latest thinking in efficacy and toxicity, |
International Standard Serial Number | 2056-452X |
500 ## - GENERAL NOTE | |
General note | Animated audio-visual presentation with synchronized narration. |
500 ## - GENERAL NOTE | |
General note | Title from title frames. |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Contents: USAEGFR TKIs in 2nd /3rd line therapy -- Phase II activity of EGFR TKIs in unselected NSCLC -- BR.21 study design and overall survival -- Forest plot of survival by subsets -- Is there a survival advantage for male smokers with squamous-cell carcinoma? -- Trials comparing Gefitinib to Docetaxel -- SIGN trial -- RECIST study -- INTEREST study -- EGFR inhibitors in first line therapy -- Randomized Trials of CT+/- active targeted Rx -- Maintenance of Gefitinib WJTOG 0203 -- Cetuximab in NSCLC -- EGFR interacting molecules. |
506 ## - RESTRICTIONS ON ACCESS NOTE | |
Terms governing access | Access restricted to subscribers. |
538 ## - SYSTEM DETAILS NOTE | |
System details note | Mode of access: World Wide Web. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Biomarkers. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Neoplasms |
General subdivision | complications. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Neoplasms |
General subdivision | therapy. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Receptor, Epidermal Growth Factor |
General subdivision | antagonists & inhibitors. |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Henry Stewart talks. |
Name of part/section of a work | Biomedical & life sciences collection. |
-- | Cancer therapy : latest thinking in efficacy and toxicity. |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://hstalks.com/bs/1123/">https://hstalks.com/bs/1123/</a> |
856 42 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://hstalks.com/bs/p/385/">https://hstalks.com/bs/p/385/</a> |
Materials specified | Series |
No items available.